top of page

© Artur - / Fraunhofer IZI

An Overview of Our Research

At the heart of CERTAINTY lies a sophisticated, multi-faceted approach to personalising treatment for blood cancer patients receiving CAR T cell therapies. Our methodology combines the power of computer simulations with real-world data and advanced biological analysis. We gather in-depth health records from patients over time and tap into detailed genetic and molecular information from individual cells. By integrating this information, we create virtual twins - digital replicas of patients’ unique biology - to understand how CAR T cells behave and interact at a very detailed level. This would allow us to predict how each patient might respond to therapy, helping doctors choose the most effective treatment path. Alongside this, we consider the broader human factors, such as social and healthcare system considerations, to make sure that our future virtual twins can be used effectively by healthcare professionals as a tool to support decision-making. All of this is built on a foundation of reliable software practices to ensure safety and accuracy in the medical field.

WP1 Project Management

WP2 Virtual Twin Data Integration & Management

WP3 Virtual Twin Prognostic & Predictive Modelling

WP4 Virtual Twin IT Architecture and Integration 

WP5 Ex-Vivo and In-Vitro Characterisation of Patient-Derived Samples and Cell Products

WP6 The Virtual Twin in Real World Settings

WP7 Dissemination, Communication, and Exploitation

WP8 Ethics Requirements

Overall Methodology of CERTAINTY
Structure of the 7 work packages of the CERTAINTY project.

Our Scientific Advisory Board

Clinical advice

University Hospital Centre Zagreb

Software as medical device

Berlin CERT

Digital twin for the human immune system

Université de Toulouse III - Paul Sabatier

Clinical advice

European Society for Blood and Marrow Transplantation

Science technology studies

University of Vienna

Clinical advice

European Society for Blood and Marrow Transplantation

AI trustworthiness & security


Abstract Background

What Our Coordinator Says

Kristin Reiche

Dr. Kristin Reiche, Head of the Bioinformatics Unit at Fraunhofer IZI

"For CERTAINTY, we will build on existing computer-aided models of human biology. We want to combine these with novel models for genetically modified immune cells such as CAR T cells in order to model the individual course of disease and therapy for patients."
bottom of page